D. Boral Capital Issues Pessimistic Forecast for FibroBiologics (NASDAQ:FBLG) Stock Price

FibroBiologics (NASDAQ:FBLG) had its price objective cut by D. Boral Capital from $15.00 to $7.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

FBLG has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of FibroBiologics in a research note on Friday, January 2nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.50.

FibroBiologics Price Performance

Shares of FBLG stock opened at $0.28 on Wednesday. FibroBiologics has a fifty-two week low of $0.22 and a fifty-two week high of $1.53. The stock’s 50-day moving average is $0.29 and its two-hundred day moving average is $0.39. The firm has a market cap of $19.12 million, a P/E ratio of -0.67 and a beta of -0.60.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.06. As a group, research analysts expect that FibroBiologics will post -0.53 EPS for the current year.

Insider Activity

In related news, General Counsel Ruben A. Garcia bought 140,000 shares of FibroBiologics stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the completion of the acquisition, the general counsel owned 140,000 shares in the company, valued at approximately $47,600. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On FibroBiologics

Several large investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in shares of FibroBiologics during the first quarter worth $29,000. XTX Topco Ltd increased its holdings in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after purchasing an additional 28,276 shares in the last quarter. Ethos Financial Group LLC raised its stake in shares of FibroBiologics by 100.0% in the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after purchasing an additional 24,424 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of FibroBiologics in the 2nd quarter valued at about $37,000. Finally, Marshall Wace LLP bought a new stake in shares of FibroBiologics in the second quarter valued at about $49,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.